Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

The Association between Epileptiform Activity and Autistic Symptoms in Three Cases with Tuberous Sclerosis

Kunio Yui*, George Imataka, Hitomi Sasaki, Ryoichi Shiroki

Department of Urology, Fujita Health University School of Medicine, Aichi, Toyoake, 470-1192, Japan

Abstract: This case study examined the association between epileptic activity such as epileptiform discharges and autistic symptoms; and to examine the effect of mTOR inhibitor everolimus on seizures and epileptiform discharges in three cases with TSC and autistic symptoms. The everolimus treatment improved autistic symptoms in all four cases, however, epileptiform discharges did not disappear in all four cases with everolimus treatment. Thus, epileptiform activity and autistic symptoms may be two end-results of separate brain dysfunction. The evrolimus treatment disappeared a seizure in only one case, suggesting partial overlap between mTOR hyperactivity and a seizure in small subset of cases with TSC. This study for firstly revealed that the everolimus treatment was inefficient for epileptiform discharges. Antiepileptic therapy at early stage of brain development might be effective for epileptic activity.

Keywords: tuberous sclerosis complex, seizure control, Epileptiform discharges, autistic symptoms, mTOR inhibitor

Received September 10, 2019; Revised October 24, 2019; Accepted October 30, 2019

Citation: Kunio Yui, George Imataka, Hitomi Sasaki, Ryoichi Shiroki, The Association between Epileptiform Activity and Autistic Symptoms in Three Cases with Tuberous Sclerosis. American Journal of Clinical Medicine Research, 7 (2). 57-59. January 2019. doi:10.12691/ajcmr-7-2-5

1. Introduction

Most children suffering from TSC with ASD experienced early onset of epilepsy including infantile spasms, West syndrome or focal seizures with impaired awareness [1]. Epileptic activity such as epileptiform discharges (referred to as spikes) in these seizures may contribute to the brain dysfunction as called epileptic encephalopathy,¹ which may sometimes induce autistic symptoms such as impaired communication and repetitive behavior [1]. However, the contribution of epileptiform activity to the development of autistic symptoms remains open to debate [1].

TSC is caused by mutations in the TSC1 or TSC2 genes, and induce mTOR hyperactivation, inducing neuropsychiatric impairments and epileptogenesis [2]. mTOR inhibitors (everolimus and rapamycin) improve TSC-associated seizures and ASD, and epileptiform activity such as epileptiform discharge [3]. However, there is few data on potential anti-epileptogenic action of mTOR inhibitors [4].

This study attempted to untangle the association between epileptiform discharges and autistic symptoms; and to examine the effect of everolimus on epileptiform discharges in four cases with TSC. This study may shed light on a new aspect of the neurobiological bases of ASD.

2. Case Reports

Case 1 was 10 years old male with TSC accompanied with the autistic social impairment and verbal stereotypy. A subpendymal nodule located at the left frontal area and AML were detected, meeting the TSC diagnostic criteria. At age 5 months, the patient experienced a severe epilepsy syndrome of the triad of focal epileptic spasms (West syndrome), characterized by clusters of epileptic spasms, psychomotor delay, and a specific interictal EEG pattern known as hypsarrhythmia. He continued to take anticonvulsants, however his seizures persisted. Thus, he received focal resection of a subpendymal nodule, and his seizure disappeared following this resection at age 2 years. However, epileptiform discharges were still detected. At age 10 years, his EEG was highly disorganized with low voltage irregular slow waves intermixed with multifocal spikes. At age 6 years, his ASD symptoms gradually developed. To improve his autistic symptoms and EEG abnormalities, he was treated with everolimus (3.6 mg/day for 24 weeks). The everolimus treatment disappeared autistic symptoms. However, epileptiform discharges persisted.

Case 2 was 9 years old girl with TSC accompanied with the autistic social impairment. At age 7 years, a subdendymal nodule on left anterior horn of lateral ventricle was detected. At age 4 months, she experienced focal seizures with impaired awareness characterized by clusters of epileptic spasms from right face to left hand seizure, following language development delay. She was treated with anticonvulsants, and her seizure disappeared. At age 2 years, she experienced re-occurrence of focal seizure with impaired awareness and treated with clonazepam, resulting disappearance of her seizure. At age 7 years, her EEG indicated high voltage irregular slow waves intermixed with spikes and polyspikes (hypsarhythmia). At age 4 years, her impaired social interaction gradually developed. Everolimus treatment (2.5 mg/day for 24 weeks) improved social impairment, however, her seizures and epileptiform discharges did not disappear. Thus, at age 9 years, she received complete corpus callosotomy, leading to disappearances of seizures and epileptiform discharges.

Figure 1. Electroencephalographic recordings of case 2

Case 3 was age 6 years old girl with TSC accompanied with autistic social impairments and stereotyped behaviors. At age 6 months, SEGA located at the right foramen of Monro and subpendymal nodules located at both side interventricular form were detected, meeting the diagnostic criteria for TSC. At age 6 months, she exhibited infantile spasms. At age 13 months, she experienced her first episode of focal seizures with impaired awareness. The patient was treated with various anticonvulsants, however, her epilepsy gradually increased in frequency and severity. Her EEG frequently showed spikes and spike-and-wave complexes at the central areas. Since she was 7 months of age, she developed impaired social interaction. She had difficulty with motor coordination. At age six years, everolimus treatment (3.0 mg/day for 24 weeks) improved autistic symptoms and disappearance of her seizures, however, epileptic discharges persisted.

3. Discussion

Epileptic seizures of case 1 disappeared with antiepileptic therapy before everolimus treatment. Epileptiform discharges disappeared in all four cases during and after the everolimus treatment. Several neurological studies confirmed the relationship of the epileptiform discharges and autistic symptoms [1]. While, some longitudinal case studies postulated that autistic symptoms and seizures may be separate phenotype from a standpoint of mechanisms [1]. Thus, the association between epileptiform discharges and autistic symptoms remains open to debate. This study revealed no overlap between the epileptiform discharges and autistic suymptoms in all cases. The core TSC pathophysiology, hyperactivation of the mTOR pathway, induces impaired brain functioning such as abnormalities in intracellular signaling inducing altered neuronal connections, leading to the autistic symptoms and epilepsy [2]. The everolimus treatment improved autistic symptoms in all four cases. Previous studies indicated that mTOR hyperactivity is critical for epileptiform discharges, suggesting that mTOR inhibitors may disappear epileptiform discharges [3]. However, epileptiform discharges did not disappeared with everolimus treatment in all cases. Our finding, considering together with the previous postulation that no clinical data on anti-epileptogenic activity of everolimus [5], and mTOR inhibitors have only stalling effect for epilepsy progress [4], our above finding may be reasonable.

A previous review article suggested overlap in the presentation of epileptogenesis and autistic symptoms [1]. In this study, although everolimus treatment improved autistic symptoms in all four cases, epileptiform discharges did not disappear in all four cases with everolimus treatment. Thus, epileptiform activity and autistic symptoms may be two separate terminal-output of brain dysfunction. Additionally, the present finding that the everolimus treatment disappeared seizure in only case 4 suggested partial overlap between mTOR hyperactivity and seizures in small subset of cases with TSC.

There are few information on the most optional treatment for refractory seizures associated with TSC[5]. Although mTOR inhibitors have efficacy in the treatment of TSC-associated seizures [3], this study for firstly revealed that everolimus treatment may inefficient for epileptiform discharges. Antiepileptic therapy at early stage of brain development might be effective for epileptic activity.

References

[1]   | Srivastava S, Sahin M. Autism spectrum disorder and epileptic encephalopathy: common causes, many questions. J Neurodev Disord. 2017, 9:23.
[2]   | Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, et al. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Int J Dev Neurosci. 2013, 31: 667-78.
[3]   | Costa V, Aigner S, Vukcevic M, Sauter E, Behr K, Ebeling M, et al. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclersis. Cell Rep. 2016, 15(1):86-95.
[4]   | Wong M. mTOR as a potential treatment target for epilepsy. Future Neurol. 2012, 7:537-545.
[5]   | Ryther RC, Wong M (2012) Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep. 2012, 12(4):410-8.